<DOC>
	<DOCNO>NCT00085774</DOCNO>
	<brief_summary>This study design examine effectiveness two bronchodilator inhaler patient exercise-induced asthma .</brief_summary>
	<brief_title>Comparison Two Bronchodilator Inhalers Adolescents Adults With Exercise-Induced Asthma</brief_title>
	<detailed_description />
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Asthma , Exercise-Induced</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Provide write informed consent Male nonpregnant , nonnursing female age 12 40 year , inclusive , first screen visit Have exerciseinduced bronchospasm ( EIB ) , without asthma , demonstrate ≥15 % decrease prechallenge absolute FEV1 observe 60 minute follow exercise challenge conduct first screen visit Predicted FEV1 ≥70 % age , height , gender , , applicable , race follow 8 hour period without [ beta ] 2 agonist use Have contraindication exercise maximally Ability perform spirometry reproducibly ( i.e. , difference two high FEV1 value minimum three maximum eight value obtain first screen visit must exceed 0.2 L ) Ability selfperform PEF ( peak expiratory flow ) determination handheld peak flow meter Can tolerate withdrawal applicable medication qualification screen visit Normal chest X ray , , abnormal , consistent asthma show evidence active disease Otherwise healthy individual clinically acceptable medical history , physical examination , vital sign , 12 lead ECG ( electrocardiogram ; 30 second Lead II rhythm strip ) Body mass index ( BMI ) 19 29 kg/m2 ( BMI = weight [ kg ] / height2 [ ] ) Nonsmokers least one year prior first screen visit maximum smoking history tenpack year ( i.e. , equivalent 20 cigarette per day 10 year ) . Allergy sensitivity albuterol component formulation use drug Exposure investigational drug within 30 day prior first screen visit Require continuous treatment [ beta ] blocker ( administer route ) , MAO ( monoamine oxidase ) inhibitor , tricyclic antidepressant , cromones ( route ) , antileukotrienes , and/or systemic corticosteroid Treated oral injectable corticosteroid within 12 week prior first screen visit The prescribed dose regimen require inhaled corticosteroid stable least four week prior first screen visit NOTE : Patients require subsequent dosage adjustment drug product must discontinue study . Inability tolerate unwillingness comply require washout period applicable medication xanthinecontaining food beverage prior screen visit Treatment emergency room asthmatic symptom hospitalization asthmatic symptom within twelve month prior first screen visit Experienced upper respiratory tract infection and/or sinusitis associate exacerbation asthmatic symptom require emergency room treatment and/or hospitalization and/or treatment oral injected corticosteroid resolve within four week prior screen visit History and/or presence clinicallysignificant acute chronic disease , include limited bronchitis , emphysema , active tuberculosis , bronchiectasis , cystic fibrosis , clinically significant cardiovascular disease ( include cardiac arrhythmia uncontrolled hypertension ) , clinically significant hepatic , renal , endocrine dysfunction , stroke , uncontrolled diabetes , hyperthyroidism , convulsive disorder , neoplastic disease basal cell carcinoma skin Known suspect substance abuse ( e.g. , alcohol , marijuana , etc . ) and/or presence medical psychological condition investigator 's opinion preclude study enrollment . Are employee study site family member associate conduct study site Previous enrollment IVAX Researchsponsored Albuterol HFA aerosol asthma study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>albuterol</keyword>
	<keyword>aerosol inhaler</keyword>
	<keyword>metered-dose inhaler</keyword>
	<keyword>breath-actuated inhaler</keyword>
	<keyword>exercise-induced bronchospasm</keyword>
</DOC>